Summary
Mitochondrial dysfunction is a feature of neurodegenerative diseases, including Alzheimer’s disease (AD). Using whole-genome sequencing, we assessed mitochondrial DNA (mtDNA) heteroplasmy levels and mtDNA copy number (mtDNAcn) in 1,361 human brain samples of five brain regions from three studies. Multivariable analysis of ten common brain pathologies identified tau pathology in the dorsolateral prefrontal cortex and TDP-43 pathology in the posterior cingulate cortex as primary drivers of reduced mtDNAcn in the aged human brain. Amyloid-β pathology, age, and sex were not associated with mtDNAcn. Further, there is evidence for a direct effect of mitochondrial health on cognition. In contrast, while mtDNA heteroplasmy levels increase by about 1.5% per year of life in the cortical regions, we found little evidence for an association with brain pathologies or cognitive functioning. Thus, our data indicates that mtDNA heteroplasmy burden is unlikely to be involved in the pathogenesis of late-onset neurodegenerative diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by NIH grants U01AG046152 (PLD, DAB), U01AG061356 (PLD, DAB), P30AG010161 (DAB), R01AG015819 (DAB), and R01AG017917 (DAB).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Religious Orders Study (ROS) and the Rush Memory and Aging Project (MAP) were approved by the Institutional Review Board of Rush University Medical Center. The Mayo study was approved by the Mayo Clinic Institutional Review Board. The MSBB study was approved by the Mount Sinai and JJ Peters VA Medical Center Institutional Review Boards.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw and processed data (WGS, proteomics, RNA-seq), called variants, and analysis output (mtDNA, mtDNA heteroplasmy levels) from the three studies (see Table S6 for details) are available via the AD Knowledge Portal (https://adknowledgeportal.org). The AD Knowledge Portal is a platform for accessing data, analyses, and tools generated by the Accelerating Medicines Partnership (AMP-AD) Target Discovery Program and other National Institute on Aging (NIA)-supported programs to enable open-science practices and accelerate translational learning. The data, analyses and tools are shared early in the research cycle without a publication embargo on secondary use. Data is available for general research use according to the following requirements for data access and data attribution (https://adknowledgeportal.org/DataAccess/Instructions). For access to content described in this manuscript see: https://doi.org/10.7303/syn25618990 ROSMAP pathologic and phenotypic data are available at https://www.radc.rush.edu. R and shell scripts used to generate figures and analysis results are deposited at GitHub: https://github.com/cu-ctcn/mtDNA